UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression

European journal of haematology, 2023-04, Vol.110 (4), p.371-378

2023

Link zum Volltext

Verfügbarkeit prüfen

Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

European journal of haematology, 2023-07, Vol.111 (1), p.63-71

2023

Link zum Volltext

Verfügbarkeit prüfen

ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia

Scientific reports, 2020-05, Vol.10 (1), p.8349, Article 8349

2020

Link zum Volltext

Verfügbarkeit prüfen

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Haematologica (Roma), 2022-03, Vol.107 (3), p.715

2022

Link zum Volltext

Verfügbarkeit prüfen

Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury

Journal of oncology pharmacy practice, 2022-03, Vol.28 (2), p.508-515

2022

Link zum Volltext

Verfügbarkeit prüfen

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Annals of hematology, 2022-04, Vol.101 (4), p.755-762

2022

Link zum Volltext

Verfügbarkeit prüfen

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Vaccines (Basel), 2023-03, Vol.11 (4), p.775

2023

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Leukemia, 2020-01, Vol.34 (1), p.293-295

2020

Link zum Volltext

Verfügbarkeit prüfen

Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting

Rambam Maimonides medical journal, 2014-10, Vol.5 (4), p.e0027-e0027

2014

Link zum Volltext

Verfügbarkeit prüfen

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Blood, 2021-11, Vol.138 (Supplement 1), p.2458-2458

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical Features, Laboratory Characteristics, and Response to Therapy in Patients with Acute Undifferentiated Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.1505-1505

2018

Link zum Volltext

Verfügbarkeit prüfen

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

Cancer Immunology, Immunotherapy, 2023-03, Vol.72 (3), p.707-718

2023

Link zum Volltext

Verfügbarkeit prüfen

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Blood, 2022-11, Vol.140 (Supplement 1), p.6534-6535

2022

Link zum Volltext

Verfügbarkeit prüfen

Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation

Cancer Immunology, Immunotherapy, 2018-05, Vol.67 (5), p.739-748

2018

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Blood, 2018-11, Vol.132 (Supplement 1), p.5206-5206

2018

Link zum Volltext

Verfügbarkeit prüfen

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Blood, 2022-11, Vol.140 (Supplement 1), p.3816-3817

2022

Link zum Volltext

Verfügbarkeit prüfen

Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review

American journal of blood research, 2021-01, Vol.11 (1), p.111-117

2021

Link zum Volltext

Verfügbarkeit prüfen

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Blood, 2019-11, Vol.134 (Supplement_1), p.5654-5654

2019

Link zum Volltext

Verfügbarkeit prüfen

Chronic Lymphocytic Leukemia Cells Acquire a Regulatory B-Cell Phenotype Modified By PD1 Signaling

Blood, 2014-12, Vol.124 (21), p.3319-3319

2014

Link zum Volltext

Verfügbarkeit prüfen

TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells

Blood, 2016-12, Vol.128 (22), p.4377-4377

2016

Link zum Volltext

Verfügbarkeit prüfen

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Blood, 2019-11, Vol.134 (Supplement_1), p.5321-5321

2019

Link zum Volltext

Verfügbarkeit prüfen

Chronic Lymphocytic Leukemia Cells Exhibit Inhibitory Properties of Regulatory B Cells

Blood, 2012-11, Vol.120 (21), p.3874-3874

2012

Link zum Volltext

Verfügbarkeit prüfen

Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review

American journal of blood research, 2021, Vol.11 (1), p.111-117

2021

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Leukemia, 2020, Vol.34 (1), p.293-295

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(22)
Bücher
(2)
Berichte
(2)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression

Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Minimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Clinical Features, Laboratory Characteristics, and Response to Therapy in Patients with Acute Undifferentiated Leukemia

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Chronic Lymphocytic Leukemia Cells Acquire a Regulatory B-Cell Phenotype Modified By PD1 Signaling

TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Chronic Lymphocytic Leukemia Cells Exhibit Inhibitory Properties of Regulatory B Cells

Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Obstetrics and Gynecology: The Essentials of Clinical Care

Aktive Filter

Suchergebnisse filtern